Literature DB >> 20709051

The effect of UGT1A1 promoter polymorphism on bilirubin response to hydroxyurea therapy in hemoglobinopathies.

Khushnooma Y Italia1, Farah F Jijina, Dipty Jain, Rashid Merchant, Anita H Nadkarni, Malay Mukherjee, Kanjaksha Ghosh, Roshan B Colah.   

Abstract

OBJECTIVES: Hydroxyurea is known to reduce ineffective erythropoiesis and thereby hemolysis leading to a reduction in bilirubin levels in patients with hemoglobinopathies. However, the effect of hydroxyurea on hyperbilirubinemia in relation to the UGT1A1 gene promoter polymorphism is not known in Indian patients with different hemoglobinopathies. DESIGN AND METHODS: We studied 112 patients (77 sickle cell anemia, 22 β-thalassemia intermedia and 13 HbE-β-thalassemia) who were on hydroxyurea therapy for 2 years for their response towards hyperbilirubinemia associated with UGT1A1 promoter polymorphism.
RESULTS: The patients with (TA)(7)/(TA)(7) repeats had significantly higher serum bilirubin levels than those with (TA)(6)/(TA)(6) repeats in all the groups and the reduction in serum bilirubin after hydroxyurea therapy was still higher among patients with (TA)(7)/(TA)(7) repeats when compared with (TA)(6)/(TA)(6) repeats.
CONCLUSIONS: Higher bilirubin levels were associated with the (TA)(7)/(TA)(7) sequence however they did not come down to normal levels after hydroxyurea therapy.
Copyright © 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20709051     DOI: 10.1016/j.clinbiochem.2010.08.006

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  4 in total

1.  A genome-wide association study of total bilirubin and cholelithiasis risk in sickle cell anemia.

Authors:  Jacqueline N Milton; Paola Sebastiani; Nadia Solovieff; Stephen W Hartley; Pallav Bhatnagar; Dan E Arking; Daniel A Dworkis; James F Casella; Emily Barron-Casella; Christopher J Bean; W Craig Hooper; Michael R DeBaun; Melanie E Garrett; Karen Soldano; Marilyn J Telen; Allison Ashley-Koch; Mark T Gladwin; Clinton T Baldwin; Martin H Steinberg; Elizabeth S Klings
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

2.  Uridine diphosphate glucuronosyl transferase 1A (UGT1A1) promoter polymorphism in young patients with sickle cell anaemia: report of the first cohort study from Nigeria.

Authors:  Oladele Simeon Olatunya; Dulcineia Martins Albuquerque; Ganiyu Olusola Akanbi; Olufunso Simisola Aduayi; Adekunle Bamidele Taiwo; Opeyemi Ayodeji Faboya; Tolorunju Segun Kayode; Daniela Pinheiro Leonardo; Adekunle Adekile; Fernando Ferreira Costa
Journal:  BMC Med Genet       Date:  2019-10-16       Impact factor: 2.103

Review 3.  Do Genetic Polymorphisms Affect Fetal Hemoglobin (HbF) Levels in Patients With Sickle Cell Anemia Treated With Hydroxyurea? A Systematic Review and Pathway Analysis.

Authors:  Rahyssa Rodrigues Sales; Bárbara Lisboa Nogueira; Jéssica Abdo Gonçalves Tosatti; Karina Braga Gomes; Marcelo Rizzatti Luizon
Journal:  Front Pharmacol       Date:  2022-01-21       Impact factor: 5.810

4.  UGT1A1 promoter polymorphism associated with serum bilirubin level in Saudi patients with sickle cell disease.

Authors:  Zainab Hamad; Abdullah Aljedai; Rabih Halwani; Abdulrahman AlSultan
Journal:  Ann Saudi Med       Date:  2013 Jul-Aug       Impact factor: 1.526

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.